|
Delayed
Nasdaq
22:56:35 26/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.415 USD | -1.74% |
|
-7.52% | -82.38% |
| 10-07 | Top Midday Gainers | MT |
| 10-07 | Lipocine Inc. Through Verity Pharmaceuticals Inc Announces Health Canada Approval of Tlando for Testosterone Replacement Therapy in Adult Males | CI |
Company Valuation: Lipocine Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 87.5 | 35.21 | 14.83 | 26.1 | 44.58 | 11.87 | - | - |
| Change | - | -59.76% | -57.88% | 75.97% | 70.83% | -73.37% | - | - |
| Enterprise Value (EV) | 87.5 | 35.21 | 14.83 | 26.1 | 44.58 | 11.87 | 11.87 | 11.87 |
| Change | - | -59.76% | -57.88% | 75.97% | 70.83% | -73.37% | 0% | 0% |
| P/E | -99.1x | -3.32x | -0.9x | - | -4.54x | -0.93x | -1.07x | -1.52x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0x | - | - | 0.1x | 0.1x | 0.1x |
| Capitalization / Revenue | 5.42x | 70.4x | -5.2x | 2.33x | 22.6x | 18.8x | 15.9x | 9.89x |
| EV / Revenue | 0x | 0x | -0x | 0x | 0x | 18.8x | 15.9x | 9.89x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -0.89x | -0.71x | -0.81x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.17 | -2.04 | -3.1 | - | -1.77 | -1.545 | -1.34 | -0.95 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 16.14 | 0.5 | -2.851 | 11.2 | 1.977 | 0.6312 | 0.745 | 1.2 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | 3.146 | -12.12 | -17.93 | -1.155 | -10.37 | -13.36 | -16.6 | -14.7 |
| Net income 1 | -0.6344 | -10.76 | -16.35 | 0.00835 | -9.628 | -12.64 | -16.22 | -14.2 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 16.849 | 6.763 | 2.790 | 4.880 | 8.030 | 1.440 | 1.440 | 1.440 |
| Nbr of stocks (in thousands) | 5,194 | 5,207 | 5,316 | 5,348 | 5,552 | 8,244 | - | - |
| Announcement Date | 09/03/22 | 10/03/23 | 07/03/24 | 13/03/25 | 10/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.93x | - | - | - | 11.87M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.59x | 5.97x | 20.28x | -.--% | 23.67B | |
| Average | 23.99x | 26.46x | 15.70x | 0.32% | 38.31B | |
| Weighted average by Cap. | 26.72x | 25.33x | 15.91x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LPCN Stock
- Valuation Lipocine Inc.
Select your edition
All financial news and data tailored to specific country editions
